AAD VMX 2021: Deucravacitinib Outperforms Placebo and Apremilast in Plaque Psoriasis
No significant safety signals have been reported to date
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No significant safety signals have been reported to date
Only registered members have full access to PracticeUpdate content.